Betahistine - Obecure

Drug Profile

Betahistine - Obecure

Alternative Names: Histalean; OBE 101

Latest Information Update: 18 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Obecure
  • Class Pyridines; Small molecules
  • Mechanism of Action Histamine H1 receptor agonists; Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipidaemia; Obesity; Weight gain

Most Recent Events

  • 31 Dec 2010 Obecure completes a phase I trial in healthy volunteers in Romania [NCT01168336]
  • 26 Feb 2010 National Institutes of Health completes enrolment in its Phase-I trial (NCT00459992) for Obesity in USA
  • 17 Feb 2010 Grunenthal and Obecure Pharmaceuticals enter into an extension of their original strategic supply agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top